Bristol, Merck End Pargluva Collaboration
This article was originally published in The Pink Sheet Daily
Executive Summary
Bristol-Myers Squibb says it will consider pursuing commercialization of muraglitazar independently.
You may also be interested in...
AstraZeneca Discontinues PPAR Candidate Galida
Safety issues have plagued development of the diabetes treatment class.
AstraZeneca Discontinues PPAR Candidate Galida
Safety issues have plagued development of the diabetes treatment class.
Pargluva Development May Be Terminated By Bristol, Merck
Regulatory approval and commercial success of the investigational type 2 diabetes drug will require additional clinical trials that could take up to five years to complete, Bristol says.